DiscoveRx signs a worldwide agreement with GlaxoSmithKline (GSK) that allows GSK, access to PathHunter® β-Arrestin cell lines and reagents for GPCR screening.

Release date: 10/1/2009

Fremont, US - October 1, 2009 - DiscoveRx Corp. announced today the signing of a global agreement with GSK, a leading pharmaceutical company, to provide access to it’s PathHunter® β-Arrestin parental cell lines, clones and associated reagents for use in GSK’s internal GPCR Screening and Profiling efforts. The agreement was announced soon after the announcement of a major industrial/academic collaboration that includes Medical Research Council, GSK and DiscoveRx around GPCR orphan program. DiscoveRx further stated that this agreement is in addition to other similar agreements signed with other major drug discovery organizations which further validates PathHunter® ß-Arrestin as a key platform to study GPCR biology.

About DiscoveRx Corporation
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of β-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. The Company is also a recipient of two Frost and Sullivan 2008 awards: Award for Innovation in North American Healthcare Market as well as a European Product Line Strategy Award for it's GPCR Cell Based assay portfolio. For more information on DiscoveRx products, please visit www.discoverx.com.

About PathHunter® β-Arrestin Technology
PathHunter® β-Arrestin assays detect primary activation events and detect binding of a ligand to the GPCR of interest by directly measuring β-Arrestin recruitment to the GPCR. Because Arrestin recruitment occurs independent of G-protein coupling status, the PathHunter® β-Arrestin assays offer a powerful and universal method that can be applied to any GPCR. Simple chemiluminescent detection coupled to no-wash, direct 3 hour assay format make these assays ideal for assay development, primary HTS and downstream lead optimization. Currently DiscoveRx offers over 140 known GPCR targets and 90 orphans GPCR assays for GPCR drug discovery.

About GlaxoSmithKline
One of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Contact
DiscoveRx Corporation
Sailaja Kuchibhatla
Sr. VP Business Development
tel | 510.979.1415 x104
skuchibhatla@discoverx.com
www.discoverx.com

GSK
Janet Morgan
R&D Communications
tel | +44.0.20.8966.2417
www.gsk.com